The latest–and perhaps final–blow to the once-promising Alzheimer’s Disease medication Aduhelm came when its maker, Biogen, said it will stop collecting data on patients who are using it. Biogen said this was a result of Medicare and Medicaid restricting coverage so severely that there would not be a substantial number of patients to follow. Even after Biogen cut its original […]
